Parkinson's disease: Dopaminergic nerve cell model is consistent with experimental finding of increased extracellular transport of α-synuclein

BMC Neuroscience

Volumn 14, Issue , 2013, Pages

  Büchel, Finja ^a   Saliger, Sandra ^a   Dräger, Andreas ^a,b   Hoffmann, Stephanie ^a   Wrzodek, Clemens ^a   Zell, Andreas ^a   Kahle, Philipp J ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Dopaminergic nerve cell model; Flux balance analysis; Parkinson's disease; SBML model

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; DOPAMINE; LEVODOPA; OXYGEN; PROTEASOME; REACTIVE OXYGEN METABOLITE; TYROSINE;

APOPTOSIS; ARTICLE; CELL FUNCTION; CELL LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; EXTRACELLULAR SPACE; LYSOSOME; MARKUP LANGUAGE; MATHEMATICAL MODEL; METABOLITE; MITOCHONDRION; MITOPHAGY; OXIDATIVE STRESS; PARKINSON DISEASE; PREDICTIVE VALUE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN TRANSPORT; SIMULATION; STEADY STATE; SYSTEMS BIOLOGY;

ALPHA-SYNUCLEIN; DOPAMINERGIC NEURONS; HUMANS; MODELS, NEUROLOGICAL; PARKINSON DISEASE;

EID: 84888239359     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-14-136     Document Type: Article

References (54)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004, 363(9423):1783-1793. http://dx.doi.org/10.1016/S0140-6736(04)16305-8, 10.1016/S0140-6736(04)16305-8, 15172778.
2. de Lau LML, Breteler MMB. Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5(6):525-535. http://dx.doi.org/10.1016/S1474-4422(06)70471-9, 10.1016/S1474-4422(06)70471-9, 16713924.
3. Zhou W, Schaack J, Zawada WM, Freed CR. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res 2002, 926(1-2):42-50. 10.1016/S0006-8993(01)03292-9, 11814405.
4. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44(4):601-607. http://dx.doi.org/10.1016/j.neuron.2004.11.005, 10.1016/j.neuron.2004.11.005, 15541309.
5. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392(6676):605-608. http://dx.doi.org/10.1038/33416, 10.1038/33416, 9560156.
6. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MMK, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304(5674):1158-1160. http://dx.doi.org/10.1126/science.1096284, 10.1126/science.1096284, 15087508.
7. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MCJ, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299(5604):256-259. http://dx.doi.org/10.1126/science.1077209, 10.1126/science.1077209, 12446870.
8. Mittag F, Büchel F, Saad M, Jahn A, Schulte C, Bochdanovits Z, Simón-Sánchez J, Nalls MA, Keller M, Hernandez DG, Gibbs JR, Lesage S, Brice A, Heutink P, Martinez M, Wood NW, Hardy J, Singleton AB, Zell A, Gasser T, Sharma M. IPDGC Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunities. Hum Mutat 2012, 33(12):1708-1718. http://dx.doi.org/10.1002/humu.22161, 10.1002/humu.22161, 22777693, IPDGC.
9. Beal MF. Parkinson's disease: a model dilemma. Nature 2010, 466(7310):S8-S10. http://dx.doi.org/10.1038/466S8a.
10. de la Fuente-Fernández R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain Fuente2004, 127(Pt 4):888-899. http://dx.doi.org/10.1093/brain/awh102.
11. Best JA, Nijhout HF, Reed MC. Homeostatic mechanisms in dopamine synthesis and release: a mathematical model. Theor Biol Med Model 2009, 6:21. http://dx.doi.org/10.1186/1742-4682-6-21, 10.1186/1742-4682-6-21, 2755466, 19740446.
12. Orth JD, Thiele I, Palsson B. What is flux balance analysis?. Nat Biotechnol 2010, 28(3):245-248. http://dx.doi.org/10.1038/nbt.1614, 10.1038/nbt.1614, 3108565, 20212490.
13. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin II, Hedley WJ, Hodgman TC, Hofmeyr JH, Hunter PJ, Juty NS, Kasberger JL, Kremling A, Kummer U, Novère NL, Loew LM, Lucio D, Mendes P, Minch E, Mjolsness ED, et al. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 2003, 19(4):524-531. 10.1093/bioinformatics/btg015, 12611808.
14. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008, 4(11):600-609. http://dx.doi.org/10.1038/ncpneuro0924.
15. Büeler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol 2009, 218(2):235-246. http://dx.doi.org/10.1016/j.expneurol.2009.03.006, 10.1016/j.expneurol.2009.03.006, 19303005.
16. Lim KL, Tan JMM. Role of the ubiquitin proteasome system in Parkinson's disease. BMC Biochem 2007, 8(Suppl 1):S13. http://dx.doi.org/10.1186/1471-2091-8-S1-S13.
17. Friguet B. Oxidized protein degradation and repair in ageing and oxidative stress. FEBS Lett 2006, 580(12):2910-2916. http://dx.doi.org/10.1016/j.febslet.2006.03.028, 10.1016/j.febslet.2006.03.028, 16574110.
18. Cookson MR. α-Synuclein and neuronal cell death. Mol Neurodegener 2009, 4:9. http://dx.doi.org/10.1186/1750-1326n-4-9n, 10.1186/1750-1326-4-9, 2646729, 19193223.
19. Alnemri ES. HtrA2 and Parkinson's disease: think PINK?. Nat Cell Biol 2007, 9(11):1227-1229. http://dx.doi.org/10.1038/ncb1107-1227n, 10.1038/ncb1107-1227, 17975547.
20. Li C, Donizelli M, Rodriguez N, Dharuri H, Endler L, Chelliah V, Li L, He E, Henry A, Stefan MI, Snoep JL, Hucka M, Le Novère N, Laibe C. BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst Biol 2010, 4:92. http://dx.doi.org/10.1186/1752-0509n-4-92n, 10.1186/1752-0509-4-92, 2909940, 20587024.
21. Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, Ladunga I, Ulitsky-Lazareva B, Muruganujan A, Rabkin S, Vandergriff JA, Doremieux O. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 2003, 31:334-341. 10.1093/nar/gkg115, 165562, 12520017.
22. Krull M, Pistor S, Voss N, Kel A, Reuter I, Kronenberg D, Michael H, Schwarzer K, Potapov A, Choi C, Kel-Margoulis O, Wingender E. TRANSPATH: an information resource for storing and visualizing signaling pathways and their pathological aberrations. Nucleic Acids Res 2006, 34(Database issue):D546-D551. http://dx.doi.org/10.1093/nar/gkj107, 1347469, 16381929.
23. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, Jensen LJ, von Mering C. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011, 39(Database issue):D561-D568. http://dx.doi.org/10.1093/nar/gkq973, 3013807, 21045058.
24. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25:25-29. http://dx.doi.org/10.1038/75556, 10.1038/75556, 3037419, 10802651.
25. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH. PID: the Pathway Interaction Database. Nucleic Acids Res 2009, 37(Database issue):D674-D679. http://dx.doi.org/10.1093/nar/gkn653, 2686461, 18832364.
26. Elsworth JD, Roth RH. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp Neurol 1997, 144:4-9. http://dx.doi.org/10.1006/exnr.1996.6379, 10.1006/exnr.1996.6379, 9126143.
27. Naoi M, Maruyama W, Akao Y, Yi H. Dopamine-derived endogenous N-methyl-(R)-salsolinol: its role in Parkinson's disease. Neurotoxicol Teratol 2002, 24(5):579-591. 10.1016/S0892-0362(02)00211-8, 12200189.
28. Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol 2012, 8:15-21. http://dx.doi.org/10.3988/jcn.2012.8.1.15, 10.3988/jcn.2012.8.1.15, 3325428, 22523509.
29. Tompkins MM, Basgall EJ, Zamrini E, Hill WD. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 1997, 150:119-131. 1858540, 9006329.
30. Kamp F, Exner N, Lutz AK, Wender N, Hegermann J, Brunner B, Nuscher B, Bartels T, Giese A, Beyer K, Eimer S, Winklhofer KF, Haass C. Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J 2010, 29(20):3571-3589. http://www.hubmed.org/display.cgi?uids=20842103, 10.1038/emboj.2010.223, 2964170, 20842103.
31. Krebiehl G, Ruckerbauer S, Burbulla LF, Kieper N, Maurer B, Waak J, Wolburg H, Gizatullina Z, Gellerich FN, Woitalla D, Riess O, Kahle PJ, Proikas-Cezanne T, Krüger R. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS One 2010, 5(2):e9367. http://dx.doi.org/10.1371/journal.pone.0009367, 10.1371/journal.pone.0009367, 2826413, 20186336.
32. Kahle PJ, Waak J, Gasser T. DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 2009, 47(10):1354-1361. http://dx.doi.org/10.1016/j.freeradbiomed.2009.08.003, 10.1016/j.freeradbiomed.2009.08.003, 19686841.
33. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol 2010, 11(12):872-884. http://dx.doi.org/10.1038/nrm3013, 10.1038/nrm3013, 21102612.
34. Springer W, Kahle PJ. Regulation of PINK1-Parkin-mediated mitophagy. Autophagy 2011, 7(3):266-278. 10.4161/auto.7.3.14348, 21187721.
35. Johnson BN, Berger AK, Cortese GP, Lavoie MJ. The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. Proc Natl Acad Sci U S A 2012, 109(16):6283-6288. http://dx.doi.org/10.1073/pnas.1113248109, 10.1073/pnas.1113248109, 3341078, 22460798.
36. Berger AK, Cortese GP, Amodeo KD, Weihofen A, Letai A, LaVoie MJ. Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Hum Mol Genet 2009, 18(22):4317-4328. http://dx.doi.org/10.1093/hmg/ddp384, 10.1093/hmg/ddp384, 2766292, 19679562.
37. Pridgeon JW, Olzmann JA, Chin LS, Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 2007, 5(7):e172. http://dx.doi.org/10.1371/journal.pbio.0050172, 10.1371/journal.pbio.0050172, 1892574, 17579517.
38. Zhu J, Wang KZQ, Chu CT. After the banquet: Mitochondrial biogenesis, mitophagy and cell survival. Autophagy 2013, 9(9):1-14.
39. Altieri DC, Stein GS, Lian JB, Languino LR. TRAP-1, the mitochondrial Hsp90. Biochim Biophys Acta 2012, 1823(3):767-773. http://dx.doi.org/10.1016/j.bbamcr.2011.08.007, 10.1016/j.bbamcr.2011.08.007, 3263322, 21878357.
40. Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, McDonald N, Wood NW, Martins LM, Downward J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 2007, 9(11):1243-1252. http://dx.doi.org/10.1038/ncb1644, 10.1038/ncb1644, 17906618.
41. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AHV, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW. ILRRKC Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008, 7(7):583-590. http://dx.doi.org/10.1016/S1474-4422n(08)70117-0nn, 10.1016/S1474-4422(08)70117-0, 2832754, 18539534, ILRRKC.
42. Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 2012, 32(5):1602-1611. http://dx.doi.org/10.1523/JNEUROSCI.5601-11nnn.2012, 10.1523/JNEUROSCI.5601-11.2012, 3532034, 22302802.
43. Wrzodek C, Büchel F, Ruff M, Dräger A, Zell A. Precise generation of systems biology models from KEGG pathways. BMC Syst Biol 2013, 7:15. 10.1186/1752-0509-7-15, 3623889, 23433509.
44. Wrzodek C, Dräger A, Zell A. KEGGtranslator: visualizing and converting the KEGG PATHWAY database to various formats. Bioinformatics 2011, 27(16):2314-2315. http://dx.doi.org/10.1093/bioinformatics/btr377, 10.1093/bioinformatics/btr377, 3150042, 21700675.
45. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35(4):495-516. http://dx.doi.org/10.1080/01926230701320337, 10.1080/01926230701320337, 2117903, 17562483.
46. Hengartner MO. The biochemistry of apoptosis. Nature 2000, 407(6805):770-776. http://dx.doi.org/10.1038/35037710, 10.1038/35037710, 11048727.
47. Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous system. Nature 2006, 443(7113):796-802. http://dx.doi.org/10.1038/nature05293, 10.1038/nature05293, 17051206.
48. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007, 2:141-151. http://dx.doi.org/10.1038/nprot.2006.342.
49. Li J, Uversky VN, Fink AL. Effect of Familial Parkinson's Disease Point Mutations A30P and A53T on the Structural Properties, Aggregation, and Fibrillation of Human α-Synuclein. Biochem 2001, 40(38):11604-11613. http://dx.doi.org/10.1021/bi010616g.
50. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, Llorens V, Tortosa EG, del Ser T, Muñoz DG, de Yebenes JG. The new mutation, E46K, of α-synuclein causes parkinson and Lewy body dementia. Ann Neurol 2004, 55(2):164-173. http://dx.doi.org/10.1002/ana.10795, 10.1002/ana.10795, 14755719.
51. Galvin JE. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol 2006, 112(2):115-126. http://dx.doi.org/10.1007/s00401-006nn-0096-2nnn, 10.1007/s00401-006-0096-2, 16791599.
52. Junker BH, Klukas C, Schreiber F. VANTED: a system for advanced data analysis and visualization in the context of biological networks. BMC Bioinformatics 2006, 7:109. http://dx.doi.org/10.1186/1471-2105n-7-109n, 10.1186/1471-2105-7-109, 1413562, 16519817.
53. Grafahrend-Belau E, Klukas C, Junker BH, Schreiber F. FBA-SimVis: interactive visualization of constraint-based metabolic models. Bioinformatics 2009, 25(20):2755-2757. http://dx.doi.org/10.1093/bioinformatics/btp408, 10.1093/bioinformatics/btp408, 2759546, 19578041.
54. Schellenberger J, Que R, Fleming RMT, Thiele I, Orth JD, Feist AM, Zielinski DC, Bordbar A, Lewis NE, Rahmanian S, Kang J, Hyduke DR, Palsson B. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0. Nat Protoc 2011, 6(9):1290-1307. http://dx.doi.org/10.1038/nprot.2011.308, 10.1038/nprot.2011.308, 3319681, 21886097.